Germany consults on new drug pricing mechanism
This article was originally published in Scrip
Executive Summary
Germany's IQWiG, the Institute for Quality and Efficiency in Healthcare, now wants feedback on the results of a study of antidepressants trialling a pricing mechanism, the so called "efficiency frontier method", which could end up being used to determine drug prices after AMNOG pricing disagreements. According to the study, the mechanism has shown that prices of bupropion should be €2.93 rather than the current €104.88, IQWiG told Scrip.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.